JP5937523B2 - 濃縮されたタンパク質製剤およびその使用 - Google Patents

濃縮されたタンパク質製剤およびその使用 Download PDF

Info

Publication number
JP5937523B2
JP5937523B2 JP2012556165A JP2012556165A JP5937523B2 JP 5937523 B2 JP5937523 B2 JP 5937523B2 JP 2012556165 A JP2012556165 A JP 2012556165A JP 2012556165 A JP2012556165 A JP 2012556165A JP 5937523 B2 JP5937523 B2 JP 5937523B2
Authority
JP
Japan
Prior art keywords
formulation
amount
present
salt
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012556165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013521296A (ja
JP2013521296A5 (enExample
Inventor
チェン，トレイシー，ティー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytodyn Inc
Original Assignee
Cytodyn Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytodyn Inc filed Critical Cytodyn Inc
Publication of JP2013521296A publication Critical patent/JP2013521296A/ja
Publication of JP2013521296A5 publication Critical patent/JP2013521296A5/ja
Application granted granted Critical
Publication of JP5937523B2 publication Critical patent/JP5937523B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2012556165A 2010-03-01 2011-03-01 濃縮されたタンパク質製剤およびその使用 Active JP5937523B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33919110P 2010-03-01 2010-03-01
US61/339,191 2010-03-01
PCT/US2011/026647 WO2011109365A2 (en) 2010-03-01 2011-03-01 Concentrated protein formulations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016095589A Division JP6229007B2 (ja) 2010-03-01 2016-05-11 濃縮されたタンパク質製剤およびその使用

Publications (3)

Publication Number Publication Date
JP2013521296A JP2013521296A (ja) 2013-06-10
JP2013521296A5 JP2013521296A5 (enExample) 2014-04-17
JP5937523B2 true JP5937523B2 (ja) 2016-06-22

Family

ID=44542798

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012556165A Active JP5937523B2 (ja) 2010-03-01 2011-03-01 濃縮されたタンパク質製剤およびその使用
JP2016095589A Active JP6229007B2 (ja) 2010-03-01 2016-05-11 濃縮されたタンパク質製剤およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016095589A Active JP6229007B2 (ja) 2010-03-01 2016-05-11 濃縮されたタンパク質製剤およびその使用

Country Status (15)

Country Link
US (2) US9956165B2 (enExample)
EP (1) EP2542221A4 (enExample)
JP (2) JP5937523B2 (enExample)
KR (1) KR101853981B1 (enExample)
CN (2) CN105521491B (enExample)
AU (2) AU2011223805B2 (enExample)
BR (1) BR112012022223B1 (enExample)
CA (1) CA2794929C (enExample)
IL (1) IL221748B (enExample)
MX (1) MX347504B (enExample)
NZ (1) NZ602685A (enExample)
RU (1) RU2626512C2 (enExample)
SG (1) SG184355A1 (enExample)
WO (1) WO2011109365A2 (enExample)
ZA (1) ZA201207331B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101853981B1 (ko) * 2010-03-01 2018-05-02 사이토딘 인크. 농축 단백질 제형물 및 그의 용도
PT2635601T (pt) 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23
WO2013063510A1 (en) * 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
US10316095B2 (en) * 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
TWI698253B (zh) 2012-09-07 2020-07-11 美商柯赫勒斯生物科學有限公司 阿達木單抗（ａｄａｌｉｍｕｍａｂ）之穩定水性調配物
CN109999195A (zh) * 2012-09-20 2019-07-12 莫弗系统股份公司 类风湿关节炎的治疗
KR20210021153A (ko) * 2012-09-20 2021-02-24 모르포시스 아게 류마티스 관절염에 대한 치료
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
EP3050557A1 (en) 2014-05-23 2016-08-03 Ares Trading S.A. Liquid pharmaceutical composition
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
BR112017003252A2 (pt) 2014-08-20 2017-11-28 Cytodyn Inc terapia com anticorpos contra hiv como substituto de tratamento
EA039598B9 (ru) 2014-09-03 2022-03-10 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23а и фно-альфа, и его применение
WO2016054259A1 (en) 2014-10-01 2016-04-07 Arsia Therapeutics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
CN107073113A (zh) * 2014-10-18 2017-08-18 辉瑞大药厂 抗il‑7r抗体组合物
JP6781508B2 (ja) 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
EA202092609A1 (ru) 2014-12-04 2021-10-29 Янссен Байотек, Инк. Антитела к cd38 для лечения острого миелолейкоза
KR101776879B1 (ko) 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
US10894083B2 (en) 2015-01-28 2021-01-19 Pfizer Inc. Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation
IL307578A (en) 2015-02-04 2023-12-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
EP3053572A1 (en) * 2015-02-06 2016-08-10 Ares Trading S.A. Liquid pharmaceutical composition
CA2973423C (en) * 2015-02-09 2023-09-05 Ucb Biopharma Sprl Pharmaceutical formulation
EP3081942A1 (en) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample
CN108136218B (zh) 2015-05-20 2022-12-13 詹森生物科技公司 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体
US11584797B2 (en) 2015-06-23 2023-02-21 Cytodyn Inc. Inhibition of CCL5 ligand binding to CCR5 receptor and alteration of CCR5/CCL5 axis signaling in inflammation, cancer, autoimmune, and other conditions
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
WO2017057644A1 (ja) * 2015-09-30 2017-04-06 持田製薬株式会社 高濃度抗体含有液体製剤
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
RS61651B1 (sr) 2015-11-03 2021-04-29 Janssen Biotech Inc Potkožne formulacije anti-cd38 antitela i njihova upotreba
CA3019482A1 (en) 2016-03-31 2017-10-05 Vhsquared Limited Compositions
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
TWI826351B (zh) * 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
CN109562149A (zh) * 2016-08-05 2019-04-02 德国杰特贝林生物制品有限公司 C1酯酶抑制剂的药物制剂
AU2018227036B2 (en) * 2017-03-01 2021-07-08 Medimmune Limited Formulations of monoclonal antibodies
BR112019023737A2 (pt) * 2017-05-16 2020-05-26 Octapharma Ag Preparação de inibidor de c1-esterase (c1-inh), kit que consiste em um primeiro receptáculo contendo a preparação de c1-inh, kit que consiste em uma seringa pré-cheia com a preparação de c1-inh, kit que consiste em um dispositivo adequado para aplicação subcutânea, tal como um injetor no corpo e uso de histidina para aumentar a biodisponibilidade de c1-inh administrado por via subcutânea
CN111132663A (zh) * 2017-08-03 2020-05-08 爵士制药爱尔兰有限公司 包含高浓度核酸的制剂
KR102208378B1 (ko) * 2017-08-17 2021-01-28 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
WO2019055995A1 (en) 2017-09-18 2019-03-21 Cytodyn Inc. SCREENING METHODS FOR IDENTIFYING AND TREATING SUB-POPULATIONS OF HIV-1 INFECTED PATIENTS SUITABLE FOR LONG-TERM THERAPY WITH AN ANTI-CCR5 AGENT
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
IL318714A (en) 2018-05-10 2025-03-01 Regeneron Pharma Formulations that include high concentrations of VEGF receptor fusion protein
JP7266108B2 (ja) 2019-02-18 2023-04-27 イーライ リリー アンド カンパニー 治療用抗体製剤
CA3132917A1 (en) 2019-03-08 2020-09-17 Boehringer Ingelheim International Gmbh Anti-il-36r antibody formulations
CN114286690A (zh) * 2019-04-23 2022-04-05 赛诺菲 稳定的低粘度抗体配制品及其用途
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
US20230235037A1 (en) * 2020-04-22 2023-07-27 Chemomab Ltd. Method of treatment using anti-ccl24 antibody
CN111595658B (zh) * 2020-06-06 2023-11-14 宾傲 一种提取细胞中蛋白的裂解液及其制备方法
CN116034985B (zh) * 2022-12-12 2025-09-16 武汉呵尔医疗科技发展有限公司 一种细胞保护液、hpv e6/e7质控片的制备方法及应用
WO2025089468A1 (ko) * 2023-10-27 2025-05-01 주식회사 엔솔바이오사이언스 펩타이드 함유 액상제제 및 그 제조방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9800684A (es) 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
EP1441589B1 (en) * 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
BR0215216A (pt) * 2001-12-21 2004-11-16 Novo Nordisk Healthcare Ag Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
MXPA04007924A (es) 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
NZ561465A (en) 2002-02-22 2009-04-30 Pdl Biopharma Inc Anti-CCR5 antibody
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
PL215168B1 (pl) * 2002-02-27 2013-10-31 Immunex Corp Formulacja polipeptydowa
AU2004216298B2 (en) 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
EP2335725B1 (en) * 2003-04-04 2016-10-12 Genentech, Inc. High concentration antibody and protein formulations
EP1753404A1 (en) 2004-05-12 2007-02-21 Baxter International Inc. Microspheres comprising protein and showing injectability at high concentrations of said agent
EP1750751B1 (en) * 2004-06-01 2013-04-10 Ares Trading S.A. Stabilized interferon liquid formulations
WO2006007412A2 (en) * 2004-06-16 2006-01-19 Nastech Pharmaceutical Company Inc. Peptide yy formulations having increased stability and resistance to microbial agents
BRPI0615745A2 (pt) * 2005-09-12 2011-05-24 Novimmune Sa formulação de anticorpo anti-cd3
NZ567685A (en) * 2005-11-01 2011-07-29 Wyeth Corp A Factor IX formulation for injection comprising sodium chloride
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
US7705132B2 (en) * 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
KR101853981B1 (ko) * 2010-03-01 2018-05-02 사이토딘 인크. 농축 단백질 제형물 및 그의 용도

Also Published As

Publication number Publication date
JP6229007B2 (ja) 2017-11-08
AU2011223805B2 (en) 2015-10-29
CA2794929A1 (en) 2011-09-09
EP2542221A4 (en) 2013-10-23
AU2016200495A1 (en) 2016-02-18
US11571383B2 (en) 2023-02-07
KR101853981B1 (ko) 2018-05-02
CN105521491A (zh) 2016-04-27
AU2016200495B2 (en) 2017-11-09
KR20130010898A (ko) 2013-01-29
WO2011109365A2 (en) 2011-09-09
CA2794929C (en) 2018-06-05
US20180263898A1 (en) 2018-09-20
MX2012010114A (es) 2013-01-29
BR112012022223A2 (pt) 2016-07-05
EP2542221A2 (en) 2013-01-09
AU2011223805A1 (en) 2012-10-25
CN102946861B (zh) 2016-01-20
MX347504B (es) 2017-04-28
CN102946861A (zh) 2013-02-27
BR112012022223B1 (pt) 2022-08-09
ZA201207331B (en) 2014-07-30
JP2013521296A (ja) 2013-06-10
IL221748B (en) 2019-09-26
HK1223835A1 (zh) 2017-08-11
CN105521491B (zh) 2020-03-24
US9956165B2 (en) 2018-05-01
BR112012022223A8 (pt) 2017-12-05
RU2626512C2 (ru) 2017-07-28
RU2012141655A (ru) 2014-04-10
WO2011109365A3 (en) 2012-01-05
US20130216525A1 (en) 2013-08-22
SG184355A1 (en) 2012-11-29
NZ602685A (en) 2014-10-31
JP2016193911A (ja) 2016-11-17

Similar Documents

Publication Publication Date Title
JP6229007B2 (ja) 濃縮されたタンパク質製剤およびその使用
ES2748526T3 (es) Formulaciones tamponadas estables que contienen polipéptidos
US10568951B2 (en) Pharmaceutical composition of an anti-VEGF antibody
BRPI0620316A2 (pt) formulações de proteìnas com viscosidades reduzida e seus usos
US20240182554A1 (en) Protein solution formulation containing high concentration of an anti-vegf antibody
JP2017105754A (ja) 低粘度抗体組成物
WO2023011502A1 (zh) 含有抗il-4r抗体的稳定制剂
JP7792137B2 (ja) 高濃度の薬理学的に活性な抗体の新規製剤
HK1223835B (zh) 浓缩蛋白制剂及其用途
KR20230165828A (ko) 항-MUC16 x 항-CD3 이중특이적 항체를 함유하는 안정화된 제형
TW202541845A (zh) 穩定醫藥製劑
CN118056572A (zh) 含有抗il-17抗体的稳定制剂
HK40030539A (en) Liquid protein formulations containing organophosphates

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150522

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150824

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20150925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160512

R150 Certificate of patent or registration of utility model

Ref document number: 5937523

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250